Weekly docetaxel versus CMF as adjuvant chemotherapy for older women with early breast cancer: final results of the randomized phase III ELDA trial

Perrone, Francesco; Nuzzo, Francesco; Rella, Francesca Di; Gravina, Adriano; Iodice, Giovanni; Labonia, V.; Landi, G.; Pacilio, Carmen; Rossi, Emanuela; Laurentiis, Michelino De; D’Aiuto, Massimiliano; Botti, Gerardo; Forestieri, Valeria; Lauria, Rossella; Placido, Sabino De; Tinessa, Vincenza; Daniele, Bruno; Gori, Stefania; Colantuoni, Giuseppe; Barni, Sandro; Riccardi, Ferdinando; Maio, Ermelinda De; Montanino, Agnese; Morabito, Alessandro; Daniele, Gennaro; Maïo, Massimo Di; Piccirillo, Maria Carmela; Signoriello, Simona; Gallo, Ciro; Matteis, A. De

doi:10.1093/annonc/mdu564

Cited by 64 publications

(58 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Furthermore, DTX also caused the significant decrease of the white blood cells and platelets after treatment for 15 days ( Figure 8F), and this hematologic toxicity is the main side effect of DTX. 45,46 Figure 8, panel F also shows the numbers of white blood cell (WBC), red blood cell (RBC), and platelet (PLT) in tumor-bearing mice treated with DTX-loaded MTNs for 15 days, and MTN@DTX-CD did not lead to the significant decrease of WBC and PLT numbers after treatment. Overall, after injection of MTN@DTX-CD into a tumor-bearing mouse, MTN@DTX-CD could efficiently accumulate in tumor via enhanced permeability and retention effect.…”

Section: In Vivo Studies Of Us-responsive Mtnsmentioning

confidence: 99%

Reactive Oxygen Species-Manipulated Drug Release from a Smart Envelope-Type Mesoporous Titanium Nanovehicle for Tumor Sonodynamic-Chemotherapy

Shi

Chen

Wang

et al. 2015

ACS Appl. Mater. Interfaces

120

View full text Add to dashboard Cite

Despite advances in drug delivery systems (DDSs), the stimuli-responsive controlled release DDSs with high spatial/temporal resolution are still the best choice. Herein, a novel type of envelope-type mesoporous titanium dioxide nanoparticle (MTN) was developed for one-demand drug delivery platform. Docetaxel (DTX) was loaded in the pores of MTN with a high drug loading efficiency (∼26%). Then β-cyclodextrin (β-CD, a bulky gatekeeper) was attached to the outer surface of MTN via a reactive oxygen species (ROS) sensitive linker to block the pores (MTN@DTX-CD). MTN@DTX-CD could entrap the DTX in the pores and allow the rapid release until a focused ultrasound (US) emerged. A large number of ROS were generated by MTN under US radiation, leading to the cleavage of the ROS-sensitive linker; thus, DTX could be released rapidly since the gatekeepers (β-CD) were detached. Besides, the generation of ROS could also be used for tumor-specific sonodynamic therapy (SDT). Studies have shown the feasibility of MTN@DTX-CD for US-triggered DTX release and sonodynamic-chemotherapy. In the in vitro and in vivo studies, by integrating SDT and chemotherapy into one system, MTN@DTX-CD showed excellent antitumor efficacy. More importantly, this novel DDS significantly decreased the side effects of DTX by avoiding the spleen and hematologic toxicity to tumor-bearing mice.

show abstract

Section: In Vivo Studies Of Us-responsive Mtnsmentioning

confidence: 99%

Reactive Oxygen Species-Manipulated Drug Release from a Smart Envelope-Type Mesoporous Titanium Nanovehicle for Tumor Sonodynamic-Chemotherapy

Shi

Chen

Wang

et al. 2015

ACS Appl. Mater. Interfaces

120

View full text Add to dashboard Cite

show abstract

“…The lower incidence of non-hematological side effects and better compliance has made AC the preferred regimen over CMF. Substitutions with "less intensive" regimens are not as comparable, as capecitabine failed to show non-inferiority with AC in efficacy and tolerability [50], and docetaxel significantly led to increased toxicity and reduced quality of life compared to CMF [51]. Nevertheless, taxanes may be given as an alternative to anthracyclines to alleviate cardiac risks.…”

Section: Triple Negative Ebcmentioning

confidence: 99%

Controversial issues in the management of older adults with early breast cancer

Mislang

Cheung

Hamaker

et al. 2017

Journal of Geriatric Oncology

View full text Add to dashboard Cite

It is well recognized that the incidence of breast cancer increases significantly with age.Despite this, older people remain under-represented in many clinical trials and their management relies on extrapolation of data from younger patients. Providing an aggressive intervention can be challenging, particularly in less fit older patients where a conservative approach is commonly perceived to be more appropriate. The optimal management of this population is unknown and treatment decision should be personalized. This review article will discuss several controversial issues in managing older adults with early breast cancer in a multidisciplinary setting, including the role of surgical treatment of the axilla in clinically node negative disease, radiotherapy after breast conservation surgery in low-risk tumors, personalizing adjuvant systemic therapy, and geriatric assessments in breast cancer treatment decisions.

show abstract

“…A toxicidade hematológica, mucosite e náusea foram mais frequentes nas mulheres tratadas com CMF. Já as reações de alergia, fadiga, perda capilar, diarreia, dor abdominal, neuropatia, alterações cutâneas e cardiotoxicidade foram observadas nas mulheres tratadas com docetaxel, piorando a qualidade de vida pela maior incidência de reações adversas quando em comparação ao uso do protocolo CMF, que foi mais bem tolerado pelas pacientes (PERRONE et al 2015).…”

Section: Protocolo Cmfunclassified

Quimioterapia, Hormonioterapia E Novas Alternativas De Tratamento Do Adenocarcinoma Mamário

Gabriel¹,

Nepomuceno²,

Pimenta³

et al. 2017

Enci Bio

View full text Add to dashboard Cite

RESUMOO câncer de mama é um importante problema de saúde pública, com altas taxas de mortalidade relacionadas ao diagnóstico tardio. Vários são os fatores de risco que levam ao aparecimento do tumor, e as mulheres são mais frequentemente acometidas, principalmente em idade superior aos 50 anos. O tratamento de escolha é a remoção cirúrgica do tumor, radioterapia, quimioterapia e hormonioterapia, com objetivo de promover morte das células tumorais. Os tratamentos quimioterápico e hormonioterápico estão associados a uma alta incidência de efeitos adversos, o que compromete o tratamento, por reduzir a qualidade de vida da paciente. Essa incidência de reações adversas justifica a constante busca por novas formas de tratamento, que tenham ação mais seletiva, melhorando a expectativa de vida dos pacientes e as perspectivas de tratamento. PALAVRAS-CHAVE: câncer de mama, fitoterápicos, quimioterapia. CHEMOTHERAPY, HORMONIOTHERAPY AND NEW ALTERNATIVES FORTREATMENT OF MAMMARY ADENOCARCINOMA ABSTRACT Breast cancer is an important public health problem, with high mortality rates related to late diagnosis. Several are the risk factors that lead to the appearance of the tumor, and women are most frequently affected, especially in the age of 50 years. The treatment of choice is the surgical removal of the tumor, radiotherapy, chemotherapy and hormone therapy, with the goal of promoting tumor cell death. The chemotherapeutic and hormone therapy treatments are associated with a high

show abstract

Weekly docetaxel versus CMF as adjuvant chemotherapy for older women with early breast cancer: final results of the randomized phase III ELDA trial

Abstract: NCT00331097.

Cited by 64 publications

References 28 publications

Reactive Oxygen Species-Manipulated Drug Release from a Smart Envelope-Type Mesoporous Titanium Nanovehicle for Tumor Sonodynamic-Chemotherapy

Reactive Oxygen Species-Manipulated Drug Release from a Smart Envelope-Type Mesoporous Titanium Nanovehicle for Tumor Sonodynamic-Chemotherapy

Controversial issues in the management of older adults with early breast cancer

Quimioterapia, Hormonioterapia E Novas Alternativas De Tratamento Do Adenocarcinoma Mamário

Contact Info

Product

Resources

About